diabetes

Diabetes: insulin and other drugs, glucose monitors and insulin pumps.

Theme · 5 companies · 2 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • ABT Abbott Laboratories

    Sells it“Continuous glucose monitoring (CGM) sales were $6.2B versus $5.6B, up 8.3% excluding FX, reflecting continued U.S. and international adoption.”

    Latest 8-KExecutive pay ·

    Change-in-control agreements extended through Dec. 31, 2028 for named executives except CEO Robert B. Ford, whose agreement expires Dec. 31, 2026.

  • JNJ Johnson & Johnson

    Sells it“Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration).”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • LLY Eli Lilly and Company

    Sells it 53%, $34.7B a year“A glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, for the treatment of adults with type 2 diabetes in combination with diet and exercise to improve glycemic control.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.

    • Revenue$24.4BYoY +38.6%
    • Net income$6.5BYoY +15.5%
  • MDT Medtronic

    Sells it“Diabetes growth reflected the U.S. MiniMed Flex launch and international adoption of MiniMed 780G.”

    Latest 8-KPositiveDeal completedLeadership changeExecutive pay ·

    MiniMed separation completed after the exchange offer was 5.4x subscribed.

  • MRK Merck & Co.

    Sells it 4%, $2.5B a year“Januvia (sitagliptin) and Janumet (sitagliptin/metformin HCl) for the treatment of type 2 diabetes.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

Feedback